_id
6915ed75bc934aba376b1e08
Ticker
RECEF
Name
Recce Pharmaceuticals Ltd
Exchange
PINK
Address
Governor Macquarie Tower, Sydney, NSW, Australia, 2000
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.recce.com.au
Description
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Last Close
0.22
Volume
-
Current Price
0.22
Change
0
Last Updated
2026-01-06T10:07:20.143Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
63620352
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
562520
Cost Of Revenue
2055540
Gross Profit
-1493020
Operating Expenses
6934766
Operating Income
-8427786
Interest Expense
-
Pretax Income
-13692929
Net Income
-13692929
Eps
-0.05590013741593018
Dividends Per Share
-
Shares Outstanding
289183422
Income Tax Expense
-
EBITDA
-13296443
Operating Margin
-1498.2197966294532
Total Other Income Expense Net
-5265143
Cash
10448808
Short Term Investments
236631
Receivables
435268
Inventories
-
Total Current Assets
11386268
Property Plant Equipment
1028228
Total Assets
12414496
Payables
2182712
Short Term Debt
1750487
Long Term Debt
8598539
Total Liabilities
15466500
Equity
-3052004
Bs_currency_symbol
AUD
Depreciation
269666
Change In Working Capital
-181627
Cash From Operations
-13518243
Capital Expenditures
8400
Cash From Investing
-35982
Cash From Financing
22059226
Net Change In Cash
-1943806
Cf_currency_symbol
-
PE
-
PB
-17.65716856858641
ROE
448.65370425464715
ROA
-110.29790496529219
FCF
-13526643
Fcf Percent
-24.0465103462988
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
1
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
5
Net Net Investing Score
0.5
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
562520
Quarters > 0 > income Statement > cost Of Revenue
2055540
Quarters > 0 > income Statement > gross Profit
-1493020
Quarters > 0 > income Statement > operating Expenses
6934766
Quarters > 0 > income Statement > operating Income
-8427786
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-13692929
Quarters > 0 > income Statement > net Income
-13692929
Quarters > 0 > income Statement > eps
-0.05590013741593018
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
244953405
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-13296443
Quarters > 0 > income Statement > operating Margin
-1498.2197966294532
Quarters > 0 > income Statement > total Other Income Expense Net
-5265143
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
10448808
Quarters > 0 > balance Sheet > short Term Investments
236631
Quarters > 0 > balance Sheet > receivables
435268
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
11386268
Quarters > 0 > balance Sheet > property Plant Equipment
1028228
Quarters > 0 > balance Sheet > total Assets
12414496
Quarters > 0 > balance Sheet > payables
2182712
Quarters > 0 > balance Sheet > short Term Debt
1750487
Quarters > 0 > balance Sheet > long Term Debt
8598539
Quarters > 0 > balance Sheet > total Liabilities
15466500
Quarters > 0 > balance Sheet > equity
-3052004
Quarters > 0 > balance Sheet > currency_symbol
AUD
Quarters > 0 > cash Flow > net Income
-13692929
Quarters > 0 > cash Flow > depreciation
269666
Quarters > 0 > cash Flow > change In Working Capital
-181627
Quarters > 0 > cash Flow > cash From Operations
-13518243
Quarters > 0 > cash Flow > capital Expenditures
8400
Quarters > 0 > cash Flow > cash From Investing
-35982
Quarters > 0 > cash Flow > cash From Financing
22059226
Quarters > 0 > cash Flow > net Change In Cash
-1943806
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.05590013741593018
Quarters > 0 > ratios > PB
-17.65716856858641
Quarters > 0 > ratios > ROE
448.65370425464715
Quarters > 0 > ratios > ROA
-110.29790496529219
Quarters > 0 > ratios > FCF
-13526643
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-24.0465103462988
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
6946389
Quarters > 1 > income Statement > cost Of Revenue
8390858
Quarters > 1 > income Statement > gross Profit
-1444469
Quarters > 1 > income Statement > operating Expenses
13008185
Quarters > 1 > income Statement > operating Income
-14452654
Quarters > 1 > income Statement > interest Expense
660373
Quarters > 1 > income Statement > pretax Income
-14473434
Quarters > 1 > income Statement > net Income
-7735160
Quarters > 1 > income Statement > eps
-0.03377839085441408
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
228997291
Quarters > 1 > income Statement > income Tax Expense
-6738274
Quarters > 1 > income Statement > EBITDA
-6988296
Quarters > 1 > income Statement > operating Margin
-208.05995748294546
Quarters > 1 > income Statement > total Other Income Expense Net
-20780
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1943806
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
70601
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
3007739
Quarters > 1 > balance Sheet > property Plant Equipment
1199499
Quarters > 1 > balance Sheet > total Assets
4207238
Quarters > 1 > balance Sheet > payables
3372785
Quarters > 1 > balance Sheet > short Term Debt
4207267
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
9193993
Quarters > 1 > balance Sheet > equity
-4986755
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-7735160
Quarters > 1 > cash Flow > depreciation
86491
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-6923860
Quarters > 1 > cash Flow > capital Expenditures
17947
Quarters > 1 > cash Flow > cash From Investing
-407920
Quarters > 1 > cash Flow > cash From Financing
4860402
Quarters > 1 > cash Flow > net Change In Cash
1943806
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.03377839085441408
Quarters > 1 > ratios > PB
-10.102642704524285
Quarters > 1 > ratios > ROE
155.11409724359828
Quarters > 1 > ratios > ROA
-183.8536350926665
Quarters > 1 > ratios > FCF
-6941807
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.9993403767050766
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
1323482
Quarters > 2 > income Statement > cost Of Revenue
173485
Quarters > 2 > income Statement > gross Profit
-173485
Quarters > 2 > income Statement > operating Expenses
12270048
Quarters > 2 > income Statement > operating Income
-12443530
Quarters > 2 > income Statement > interest Expense
572433
Quarters > 2 > income Statement > pretax Income
-12824740
Quarters > 2 > income Statement > net Income
-10199880
Quarters > 2 > income Statement > eps
-0.0500025383940184
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
203987244
Quarters > 2 > income Statement > income Tax Expense
-2624860
Quarters > 2 > income Statement > EBITDA
-12078821
Quarters > 2 > income Statement > operating Margin
-940.2115026876073
Quarters > 2 > income Statement > total Other Income Expense Net
-381210
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
4415185
Quarters > 2 > balance Sheet > short Term Investments
207861
Quarters > 2 > balance Sheet > receivables
159428
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
5136472
Quarters > 2 > balance Sheet > property Plant Equipment
1233141
Quarters > 2 > balance Sheet > total Assets
6369614
Quarters > 2 > balance Sheet > payables
3967379
Quarters > 2 > balance Sheet > short Term Debt
224085
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
15893382
Quarters > 2 > balance Sheet > equity
-9523768
Quarters > 2 > balance Sheet > currency_symbol
AUD
Quarters > 2 > cash Flow > net Income
-10199880
Quarters > 2 > cash Flow > depreciation
173485
Quarters > 2 > cash Flow > change In Working Capital
225662
Quarters > 2 > cash Flow > cash From Operations
-6491360
Quarters > 2 > cash Flow > capital Expenditures
35625
Quarters > 2 > cash Flow > cash From Investing
-1653
Quarters > 2 > cash Flow > cash From Financing
6899639
Quarters > 2 > cash Flow > net Change In Cash
198764
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.0500025383940184
Quarters > 2 > ratios > PB
-4.712125881268842
Quarters > 2 > ratios > ROE
107.09920695254232
Quarters > 2 > ratios > ROA
-160.1334083980599
Quarters > 2 > ratios > FCF
-6526985
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-4.931676441387189
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
1323482
Quarters > 3 > income Statement > cost Of Revenue
1210130
Quarters > 3 > income Statement > gross Profit
113352
Quarters > 3 > income Statement > operating Expenses
2725842
Quarters > 3 > income Statement > operating Income
-2612490
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-5099940
Quarters > 3 > income Statement > net Income
-5099940
Quarters > 3 > income Statement > eps
-0.029171167373154894
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
174828108
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-4844652
Quarters > 3 > income Statement > operating Margin
-197.3952044682134
Quarters > 3 > income Statement > total Other Income Expense Net
-2487450
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
4415185
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
5136472
Quarters > 3 > balance Sheet > property Plant Equipment
1233141
Quarters > 3 > balance Sheet > total Assets
6369614
Quarters > 3 > balance Sheet > payables
3967379
Quarters > 3 > balance Sheet > short Term Debt
9913224
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
15893382
Quarters > 3 > balance Sheet > equity
-9523768
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-5099940
Quarters > 3 > cash Flow > depreciation
86742
Quarters > 3 > cash Flow > change In Working Capital
225662
Quarters > 3 > cash Flow > cash From Operations
-3245680
Quarters > 3 > cash Flow > capital Expenditures
17813
Quarters > 3 > cash Flow > cash From Investing
-827
Quarters > 3 > cash Flow > cash From Financing
3449820
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.029171167373154894
Quarters > 3 > ratios > PB
-4.038546902864496
Quarters > 3 > ratios > ROE
53.54960347627116
Quarters > 3 > ratios > ROA
-80.06670419902996
Quarters > 3 > ratios > FCF
-3263493
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-2.465838598484906
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2025-06-30
Annuals > 0 > income Statement > revenue
7508909
Annuals > 0 > income Statement > cost Of Revenue
10446398
Annuals > 0 > income Statement > gross Profit
-2937489
Annuals > 0 > income Statement > operating Expenses
19942951
Annuals > 0 > income Statement > operating Income
-22880440
Annuals > 0 > income Statement > interest Expense
1150276
Annuals > 0 > income Statement > pretax Income
-21428089
Annuals > 0 > income Statement > net Income
-21428089
Annuals > 0 > income Statement > eps
-0.09042328318471338
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
236975348
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-20334629
Annuals > 0 > income Statement > operating Margin
-304.71057779498994
Annuals > 0 > income Statement > total Other Income Expense Net
1452351
Annuals > 0 > income Statement > currency_symbol
AUD
Annuals > 0 > balance Sheet > cash
10448808
Annuals > 0 > balance Sheet > short Term Investments
236631
Annuals > 0 > balance Sheet > receivables
435268
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
11386268
Annuals > 0 > balance Sheet > property Plant Equipment
1028228
Annuals > 0 > balance Sheet > total Assets
12414496
Annuals > 0 > balance Sheet > payables
2182712
Annuals > 0 > balance Sheet > short Term Debt
1750487
Annuals > 0 > balance Sheet > long Term Debt
8598539
Annuals > 0 > balance Sheet > total Liabilities
15466500
Annuals > 0 > balance Sheet > equity
-3052004
Annuals > 0 > balance Sheet > currency_symbol
AUD
Annuals > 0 > cash Flow > net Income
-21428089
Annuals > 0 > cash Flow > depreciation
71852
Annuals > 0 > cash Flow > change In Working Capital
-181627
Annuals > 0 > cash Flow > cash From Operations
-20442103
Annuals > 0 > cash Flow > capital Expenditures
26347
Annuals > 0 > cash Flow > cash From Investing
-443902
Annuals > 0 > cash Flow > cash From Financing
26919628
Annuals > 0 > cash Flow > net Change In Cash
6033623
Annuals > 0 > cash Flow > currency_symbol
AUD
Annuals > 0 > ratios > PE
-0.09042328318471338
Annuals > 0 > ratios > PB
-17.082080023486206
Annuals > 0 > ratios > ROE
702.0989815216493
Annuals > 0 > ratios > ROA
-172.60538808824782
Annuals > 0 > ratios > FCF
-20468450
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-2.7258886743733344
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2024-06-30
Annuals > 1 > income Statement > revenue
6849775
Annuals > 1 > income Statement > cost Of Revenue
7216543
Annuals > 1 > income Statement > gross Profit
-366768
Annuals > 1 > income Statement > operating Expenses
14153584
Annuals > 1 > income Statement > operating Income
-22051237
Annuals > 1 > income Statement > interest Expense
846852
Annuals > 1 > income Statement > pretax Income
-22567724
Annuals > 1 > income Statement > net Income
-17661714
Annuals > 1 > income Statement > eps
-0.09972747172191687
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
177099787
Annuals > 1 > income Statement > income Tax Expense
-4906010
Annuals > 1 > income Statement > EBITDA
-21354106
Annuals > 1 > income Statement > operating Margin
-321.92644283936335
Annuals > 1 > income Statement > total Other Income Expense Net
-516487
Annuals > 1 > income Statement > currency_symbol
AUD
Annuals > 1 > balance Sheet > cash
4415185
Annuals > 1 > balance Sheet > short Term Investments
207861
Annuals > 1 > balance Sheet > receivables
159428
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
5136472
Annuals > 1 > balance Sheet > property Plant Equipment
1233141
Annuals > 1 > balance Sheet > total Assets
6369614
Annuals > 1 > balance Sheet > payables
3967379
Annuals > 1 > balance Sheet > short Term Debt
224085
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
15893382
Annuals > 1 > balance Sheet > equity
-9523768
Annuals > 1 > balance Sheet > currency_symbol
AUD
Annuals > 1 > cash Flow > net Income
-17661714
Annuals > 1 > cash Flow > depreciation
366768
Annuals > 1 > cash Flow > change In Working Capital
4266121
Annuals > 1 > cash Flow > cash From Operations
-13008658
Annuals > 1 > cash Flow > capital Expenditures
141895
Annuals > 1 > cash Flow > cash From Investing
-141895
Annuals > 1 > cash Flow > cash From Financing
16004161
Annuals > 1 > cash Flow > net Change In Cash
2853608
Annuals > 1 > cash Flow > currency_symbol
AUD
Annuals > 1 > ratios > PE
-0.09972747172191687
Annuals > 1 > ratios > PB
-4.091022916559917
Annuals > 1 > ratios > ROE
185.44880555679222
Annuals > 1 > ratios > ROA
-277.2807583002675
Annuals > 1 > ratios > FCF
-13150553
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.9198518199502903
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2023-06-30
Annuals > 2 > income Statement > revenue
4365216
Annuals > 2 > income Statement > cost Of Revenue
217155
Annuals > 2 > income Statement > gross Profit
4148061
Annuals > 2 > income Statement > operating Expenses
17108408
Annuals > 2 > income Statement > operating Income
-17325560
Annuals > 2 > income Statement > interest Expense
183265
Annuals > 2 > income Statement > pretax Income
-17388624
Annuals > 2 > income Statement > net Income
-13077422
Annuals > 2 > income Statement > eps
-0.0744246420124912
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
175713603
Annuals > 2 > income Statement > income Tax Expense
-4311202
Annuals > 2 > income Statement > EBITDA
-16988208
Annuals > 2 > income Statement > operating Margin
-396.9004053865834
Annuals > 2 > income Statement > total Other Income Expense Net
4248141
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
1561579
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
90667
Annuals > 2 > balance Sheet > inventories
135377
Annuals > 2 > balance Sheet > total Current Assets
1947459
Annuals > 2 > balance Sheet > property Plant Equipment
608410
Annuals > 2 > balance Sheet > total Assets
2555869
Annuals > 2 > balance Sheet > payables
948887
Annuals > 2 > balance Sheet > short Term Debt
147878
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
5144675
Annuals > 2 > balance Sheet > equity
-2588804
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-13077422
Annuals > 2 > cash Flow > depreciation
217155
Annuals > 2 > cash Flow > change In Working Capital
-152320
Annuals > 2 > cash Flow > cash From Operations
-12687370
Annuals > 2 > cash Flow > capital Expenditures
38633
Annuals > 2 > cash Flow > cash From Investing
-38633
Annuals > 2 > cash Flow > cash From Financing
2705647
Annuals > 2 > cash Flow > net Change In Cash
-10020355
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.0744246420124912
Annuals > 2 > ratios > PB
-14.932375204920882
Annuals > 2 > ratios > ROE
505.1530359192894
Annuals > 2 > ratios > ROA
-511.66245218358216
Annuals > 2 > ratios > FCF
-12726003
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-2.915320341536364
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2022-06-30
Annuals > 3 > income Statement > revenue
3084955
Annuals > 3 > income Statement > cost Of Revenue
187672
Annuals > 3 > income Statement > gross Profit
2897283
Annuals > 3 > income Statement > operating Expenses
13962632
Annuals > 3 > income Statement > operating Income
-14150300
Annuals > 3 > income Statement > interest Expense
11926
Annuals > 3 > income Statement > pretax Income
-14071232
Annuals > 3 > income Statement > net Income
-10986277
Annuals > 3 > income Statement > eps
-0.06246797076213324
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
175870560
Annuals > 3 > income Statement > income Tax Expense
-3084955
Annuals > 3 > income Statement > EBITDA
-10796189
Annuals > 3 > income Statement > operating Margin
-458.6874038681278
Annuals > 3 > income Statement > total Other Income Expense Net
-4423410
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
11581934
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
582708
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
12184742
Annuals > 3 > balance Sheet > property Plant Equipment
438780
Annuals > 3 > balance Sheet > total Assets
12623522
Annuals > 3 > balance Sheet > payables
481429
Annuals > 3 > balance Sheet > short Term Debt
74762
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
2562164
Annuals > 3 > balance Sheet > equity
10061358
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-10986277
Annuals > 3 > cash Flow > depreciation
187672
Annuals > 3 > cash Flow > change In Working Capital
1531855
Annuals > 3 > cash Flow > cash From Operations
-9010263
Annuals > 3 > cash Flow > capital Expenditures
40345
Annuals > 3 > cash Flow > cash From Investing
-40345
Annuals > 3 > cash Flow > cash From Financing
-240499
Annuals > 3 > cash Flow > net Change In Cash
-9291106
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.06246797076213324
Annuals > 3 > ratios > PB
3.8455567528757055
Annuals > 3 > ratios > ROE
-109.1927849103471
Annuals > 3 > ratios > ROA
-87.03020440729615
Annuals > 3 > ratios > FCF
-9050608
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-2.933789309730612
Annuals > 3 > health Score
30
Valuation > metrics > PE
-0.05590013741593018
Valuation > metrics > PB
-17.65716856858641
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
448.65370425464715
Profitability > metrics > ROA
-120.25827075210245
Profitability > metrics > Net Margin
-24.342119391310533
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-21.25620072335467
Risk > final Score
-55
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.8949127669360233
Liquidity > metrics > Quick Ratio
2.8949127669360233
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
40
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
-58
Prev Risks > 1
-57
Prev Risks > 2
-11
Prev Liquidities > 0
30
Prev Liquidities > 1
81
Prev Liquidities > 2
29
Updated At
2026-01-20T22:28:28.494Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AErdoğan, Shaquille O’Neal share court, signed balls in Istanbul | Daily Sabah - dailysabah.com
1/20/2026
Erdoğan, Shaquille O’Neal share court, signed balls in Istanbul | Daily Sabah dailysabah.com
Read more →International report - Trump tests Turkey's energy dependence on Russia with lure of US power - RFI
10/11/2025
International report - Trump tests Turkey's energy dependence on Russia with lure of US power RFI
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Recce Pharmaceuticals Ltd
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.